We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Stockholm, Sweden

ESTRO 2026

Session

Saturday
May 16
15:15 - 16:15
K2
Gastrointestinal cancers 1
Eliana La Rocca, Italy;
Tiuri Kroese, Switzerland
Poster Discussions
Clinical
15:15 - 16:15
Organ preservation in rectal cancer by "MR-guided online Adaptive dose-escalated Radiotherapy for Rectal Sparing" (MARS).
Cihan Gani, Germany
-4412
15:15 - 16:15
Short-course radiotherapy followed by Pembrolizumab plus chemotherapy versus long-course chemoradiotherapy in early low rectal cancer (TORCH-E2)
Wang Yang, China
-3594
15:15 - 16:15
Exploratory dosimetric analysis of vaginal and sexual dysfunction after radiotherapy for anal cancer in the DACG-I cohort
Johanne Steffensen, Denmark
-2271
15:15 - 16:15
Analysis of pATients with Locally Advanced rectal caNcer given neoadjuvanT radiochemotherapy with or without RT dose IntenSification: ATLANTIS II
Luca Nicosia, Italy
-1811
15:15 - 16:15
Real-world evidence on long-term recurrence patterns and predictors in rectal cancer after neoadjuvant therapy
Pieter Maerten, Belgium
-506
15:15 - 16:15
Pre-Treatment PLR and NLR Predict Local Control After Escalated-Dose SBRT in Borderline and Locally Advanced Pancreatic Cancer
Barbara Gabriela Salas Salas, Spain
-621
15:15 - 16:15
Personalizing oesophageal cancer therapy: A validated multicentre model to stratify 2-year mortality in patients receiving neoadjuvant chemoradiation.
Mark Frederiks, The Netherlands
-736
15:15 - 16:15
Age-Related Outcomes After Definitive Chemoradiotherapy for Esophageal Cancer: A Multicenter Real-World Analysis
Mau-Shin Chi, Taiwan, Province of China
-1795
15:15 - 16:15
Long-term outcomes of carbon-ion radiotherapy for hepatocellular carcinoma: A single-institutional retrospective analysis
Shingo Toyama, Japan
-2988
15:15 - 16:15
Response and acute toxicity evaluation after intensity modulated proton chemoradiotherapy for locally advanced esophageal cancer.
Yvonne Klaver, The Netherlands
-3121